Ensign Peak Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Ensign Peak Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,466	Closed	-$251K	–	1770
2023 Q2	$251K	Buy	2,466 +1,143	+86%	+$157K	﹤0.01%	1730
2023 Q1	$234K	Buy	1,323 +156	+13%	+$52.2K	﹤0.01%	1734
2022 Q4	$451K	Buy	1,167 +498	+74%	+$189K	﹤0.01%	1643
2022 Q3	$225K	Sell	669 -92	-12%	-$33.3K	﹤0.01%	1833
2022 Q2	$250K	Hold	761	–	–	﹤0.01%	1730
2022 Q1	$333K	Hold	761	–	–	﹤0.01%	1714
2021 Q4	$334K	Hold	761	–	–	﹤0.01%	1777
2021 Q3	$423K	Buy	761 +280	+58%	+$140K	﹤0.01%	1656
2021 Q2	$247K	Buy	+481	New	+$305K	﹤0.01%	1697

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Ensign Peak Advisors's TVRD Position: Q3 2023 in Review

Ensign Peak Advisors sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 2,466 shares — an estimated $251K sold.

Ensign Peak Advisors first reported a position in TVRD in Q2 2021 and held it in 9 quarters. The position peaked at $451K in Q4 2022. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

Ensign Peak Advisors reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
Ensign Peak Advisors sold 2,466 Tvardi Therapeutics shares in Q3 2023, an estimated $251K.
Ensign Peak Advisors first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 9 quarters.
Ensign Peak Advisors's Tvardi Therapeutics position peaked at $451K in Q4 2022.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.